HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer

NDA FilingORPATHYSTAGRISSOPositive

AI Analysis

Summary

HUTCHMED submitted a US NDA for ORPATHYS in combination with TAGRISSO for MET-driven EGFR-mutated lung cancer patients who have progressed on prior EGFR-TKI therapy, representing an all-oral biomarker-directed treatment option.

Outcome Details

Filing seeks approval for biomarker-directed, all-oral treatment for patients with MET overexpression or amplification after EGFR-TKI progression

Importance:7/10

Sentiment:

0.60

NDA filinglung cancerEGFR-mutatedMET-drivencombination therapybiomarker-directed

Related Companies

$HMDCF

Read the original article

Published by GlobeNewswire Clinical Studies on September 29, 2026 12:00 AM

Read Original